The Memorial Sloan Kettering Cancer Center (MSK) in New York City has announced a $400 million gift from Kenneth C. Griffin, founder and CEO of Citadel, and David Geffen, founder of the David Geffen Foundation, to advance cutting-edge cancer research and treatments.

The largest single donation in MSK’s nearly 150-year history combines nine-figure gifts from Griffin and Geffen. The funding will enable MSK to expand its clinical services and bolster the institution’s efforts to establish more robust prevention and surveillance programs and continue development of advanced technology focused on early detection, active treatment, and survivorship.

“This extraordinary gift will support MSK’s physicians and scientists as they make life-changing discoveries that will lead to new cancer therapies and improved treatments, not only for our own patients but for people across the globe,” said MSK board chair Scott M. Stuart.

“The MSK team is leading the world’s effort to defeat cancer,” said Griffin. “David and I are honored to support MSK’s incredible physicians and scientists advancing breakthroughs in research and treatment and the outstanding nurses and staff who dedicate their lives to providing compassionate care to those impacted by this disease.”

“It’s our sincere hope,” said Geffen, “that this combined gift will inspire others and enable MSK to continue to build on its reputation as one of the top cancer care providers and research centers in the world.”

(Photo credit: Getty Images/Fat Camera)